Join Growin Stock Community!

Heron therapeutics, inc.HRTX.US Overview

US StockHealthcare
(No presentation for HRTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HRTX AI Insights

HRTX Overall Performance

HRTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HRTX Recent Performance

-0.84%

Heron therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

HRTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HRTX Key Information

HRTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HRTX Profile

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Price of HRTX

HRTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HRTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.41
PB Ratio
31.07
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
73.31%
Net Margin
-13.04%
Revenue Growth (YoY)
7.36%
Profit Growth (YoY)
7.50%
3-Year Revenue Growth
10.57%
3-Year Profit Growth
19.20%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.41
PB Ratio
31.07
Price-to-FCF
-
Gross Margin
73.31%
Net Margin
-13.04%
Revenue Growth (YoY)
7.36%
Profit Growth (YoY)
7.50%
3-Year Revenue Growth
10.57%
3-Year Profit Growth
19.20%

  • When is HRTX's latest earnings report released?

    The most recent financial report for Heron therapeutics, inc. (HRTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HRTX's short-term business performance and financial health. For the latest updates on HRTX's earnings releases, visit this page regularly.

  • What is the operating profit of HRTX?

    According to the latest financial report, Heron therapeutics, inc. (HRTX) reported an Operating Profit of 38K with an Operating Margin of 0.09% this period, representing a decline of 99.09% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HRTX's revenue growth?

    In the latest financial report, Heron therapeutics, inc. (HRTX) announced revenue of 40.59M, with a Year-Over-Year growth rate of -0.47%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does HRTX have?

    At the end of the period, Heron therapeutics, inc. (HRTX) held Total Cash and Cash Equivalents of 28.65M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does HRTX go with three margins increasing?

    In the latest report, Heron therapeutics, inc. (HRTX) did not achieve the “three margins increasing” benchmark, with a gross margin of 72.6%%, operating margin of 0.09%%, and net margin of -7.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HRTX's profit trajectory and future growth potential.

  • Is HRTX's EPS continuing to grow?

    According to the past four quarterly reports, Heron therapeutics, inc. (HRTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HRTX?

    Heron therapeutics, inc. (HRTX)'s Free Cash Flow (FCF) for the period is -9.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 26.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.